Malaria study - bulaquine versus primaquine

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN50134587

Enrollment

Registered

2006-03-03

Start date

2003-06-01

Completion date

Unknown

Last updated

2017-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uncomplicated P. falciparum malaria Infections and Infestations Uncomplicated P. falciparum malaria

Interventions

Patients are randomised to receive either one of two gametocytocidal drugs: bulaquine 75 mg or primaquine 45 mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged more than 16 years 2. Uncomplicated Plasmodium falciparum malaria 3. Gametocyte count more than 55 /ul within 72 hours of diagnosis, irrespective of asexual parasitemia 4. Willing to give written, informed consent

Exclusion criteria

Exclusion criteria: 1. Pregnancy 2. Lactation 3. Allergy to primaquine or bulaquine 4. Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency 5. Co-infection with Plasmodium vivax

Design outcomes

Primary

Measure	Time frame
Gametocytemia at days 8, 15, 22 and 29 of follow-up	—

Secondary

Measure	Time frame
Gametocyte viability at days 8, 15, 22 and 29	—

Countries

India

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026